Pictet Asset Management Ltd. increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,611 shares of the biotechnology company’s stock after purchasing an additional 3,900 shares during the period. Pictet Asset Management Ltd. owned approximately 0.23% of United Therapeutics Corporation worth $11,673,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Eagle Global Advisors LLC acquired a new stake in shares of United Therapeutics Corporation during the second quarter worth $206,000. TLP Group LLC acquired a new stake in shares of United Therapeutics Corporation during the second quarter worth $246,000. HPM Partners LLC grew its stake in shares of United Therapeutics Corporation by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares during the period. Fort L.P. grew its stake in shares of United Therapeutics Corporation by 5.2% during the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 99 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in United Therapeutics Corporation by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 95 shares during the period.

TRADEMARK VIOLATION WARNING: “Pictet Asset Management Ltd. Has $11.67 Million Position in United Therapeutics Corporation (UTHR)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/08/pictet-asset-management-ltd-has-11-67-million-position-in-united-therapeutics-corporation-uthr.html.

UTHR has been the subject of a number of research analyst reports. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 13th. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics Corporation has a consensus rating of “Hold” and an average price target of $132.82.

In other news, Director Christopher Causey sold 580 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the transaction, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 2,176 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the completion of the transaction, the chief executive officer now directly owns 3,245 shares in the company, valued at approximately $412,471.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,969 shares of company stock worth $2,358,212. Company insiders own 7.80% of the company’s stock.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at $122.30 on Wednesday. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89. The stock has a market capitalization of $5,272.18, a PE ratio of 10.76 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. United Therapeutics Corporation’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.23 earnings per share. equities analysts expect that United Therapeutics Corporation will post 11.92 earnings per share for the current fiscal year.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.